MOCA: Business Partnerships, Regulatory Requirements and Operations
Medicinal Organic Cannabis Australia (MOCA) has described a business strategy involving international marketing, regulatory preparation, intellectual property and potential expansion into overseas markets. The company's published statements about partnerships, licences, facilities and expansion plans should be independently verified before being relied upon for commercial or investment decisions.
Marketing partnership
MOCA has stated that it developed a strategic partnership with a medical cannabis digital marketing company to promote products internationally, including through OrganicMarijuana.com.
The scope of the partnership, the parties' contractual responsibilities and the nature of any marketing arrangements should be confirmed through current agreements and independent documentation.
New Zealand expansion plans
MOCA has stated that it submitted proprietary Standard Operating Procedures (SOPs) to the New Zealand Government. The procedures were described as addressing security, safety and regulatory requirements for the construction and operation of a cannabis research facility.
The company has also described plans to establish a cultivation centre and wholesale distribution networks in New Zealand. Submission of procedures does not establish that they were approved, that the proposed facility received the necessary licences, or that commercial operations commenced. These matters require confirmation from the relevant New Zealand authorities.
Intellectual property and regulatory documentation
MOCA has identified several areas of intellectual property and regulatory documentation, including:
Standard Operating Procedures for security and operational controls.
Drugs and poisons control procedures.
Documentation intended to support compliance with applicable medicines and poisons legislation.
Procedures relating to the handling, storage and distribution of medicinal cannabis products.
The existence, ownership, scope and legal status of these materials should be established through documentary evidence. Operational procedures and regulatory submissions are not necessarily equivalent to granted intellectual property rights or government approvals.
Licences and regulatory compliance
MOCA's published description refers to Australian import and export permissions and New South Wales wholesale supply and manufacturing licences.
The status and scope of any such permissions should be checked directly with the relevant regulatory authorities. Verification should establish the licence holder, authorised activities, product categories, conditions, expiry dates and any restrictions.
The company also refers to the Poisons and Therapeutic Goods Act 1966 (NSW). Any description of its regulatory position should reflect the legislation and licence conditions applicable to the relevant activities.
Facilities and distribution
MOCA has described operating a pharmaceutical-grade warehouse and distribution facility in Eastern Creek, New South Wales, with an international distribution focus.
Claims about the facility's ownership, approval status, operating capacity, certifications and authorised activities require independent supporting records. A facility's description as pharmaceutical-grade or government-approved should not be treated as verified without evidence of the relevant approvals and standards.
Due diligence considerations
Before relying on MOCA's published business and operational statements, investors and commercial partners should review:
Current company and ownership records.
Executed partnership agreements.
Regulatory submissions and written approval decisions.
Current import, export, wholesale and manufacturing licences.
Evidence of intellectual property ownership.
Facility approvals, inspections and relevant certifications.
Evidence that overseas expansion plans have progressed to authorised operations.
MOCA's statements provide an outline of its described business strategy. Independent verification is necessary to distinguish proposed activities, submitted documentation and company-reported arrangements from granted approvals and established operations.